Background: Inflammatory bowel disease (IBD) always progresses to colorectal cancer (CRC) which is the second most frequent cause of
death by cancer. It is about 2% of population in the lifetime worldwide who at the risk for development of CRC. Oxaliplatin is an effective
anticancer drug used for the treatment of advanced CRC; however, it always causes a robust painful neuropathy.
Pholidota chinensis
is a Chinese
folk herbal medicine which was used for treatment of inflammation such as gastroenteritis, duodenal ulcer and bronchitis.
Materials and Methods: The azoxymethane (AOM) and dextran sulfate sodium (DSS) were used to induce the colon tumor of mice. The effect
of
Pholidota chinensis on colon tumorigenesis was evaluated. Immunohistochemistry and semi-quantitative RT-PCR were used to detect the
expression of toll-like receptor 4 (TLR4) and cyclooxygenase-2 (COX-2) in colon.
Results: Pholidota chinensis can alleviate the colon tumorigenesis. The prevention effects of
Pholidota chinensis are similar to oxaliplatin.
Specifically, administration of
Pholidota chinensis solution suppresses the expression of the proliferating cell nuclear antigen (PCNA), toll-like
receptor 4 (TLR4) and cyclooxygenase-2 (COX-2).
Conclusion: Our findings suggested that
Pholidota chinensis participate in the regulation of colon cancer development through inhibiting the
expression of TLR4 and COX-2.
